Given the high volume of information about the relevance of Bcl-2 inhibitors in hematologic malignancies, including acute myeloid leukemia (AML), mature B-Cell malignancies and lymphoid malignancies [11,12,13], this article will focus mainly on Bcl-2 inhibitor application in solid tumors. Here, BCL2 is linked to hematologic disorder.